Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020
April 14th 2020
SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected for a poster short talk presentation as part of the high-impact paper presentation program at the American Association for Cancer Research (AACR) Virtual Annual Meeting, scheduled for 27 and 28 April.
This presentation was originally accepted as a late-breaking poster for the AACR Annual Meeting prior to the event being rescheduled as two virtual events due to the ongoing COVID-19 pandemic, including AACR Virtual Annual Meetings I and II. The data in this presentation relates to Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein based on the LAG-3 immune control mechanism, as part of a combination treatment with pembrolizumab, an anti-PD-1 therapy.
|Title:||‘Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab’|
|Date:||Monday, April 27, 2020|
|Session:||VPO.CT02.Phase II Clinical Trials: CT202|
|Presenter:||Dr. Martin Forster, MBBS FRCP PhD, TACTI-002 clinical trial Principal Investigator, University College London Cancer Institute in the United Kingdom|
The abstract title was published today on the AACR website at https://www.abstractsonline.com/pp8/#!/9045/presentation/10803.
The submitted abstract and the virtual poster presentation will also be accessible on Immutep’s website at www.immutep.com/investors-media/presentations.html on the day of the poster presentation.
TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line HNSCC or NSCLC in first and second line.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; firstname.lastname@example.org
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; email@example.com